HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lindberg, C. Articles by Oldfors, A. Search for Related Content PubMed PubMed Citation Articles by Lindberg, C. Articles by Oldfors, A. Related Collections Autoimmune diseases Muscle disease All Clinical trials Clinical trials Observational study (Cohort, Case control)

Anti–T-lymphocyte globulin treatment in inclusion body myositis

A randomized pilot study

From the Departments of Neurology (Dr. Lindberg), Rheumatology (Drs. Trysberg and Tarkowski), and Pathology (Dr. Oldfors), Sahlgrenska University Hospital, Sahlgrenska NeuroMuscular Center, Gothenburg, Sweden.

Address correspondence and reprint requests to Dr. Christopher Lindberg, NeuroMuscular Center, Department of Neurology, Sahlgrenska University Hospital/Molndal, S-431 80 Molndal, Sweden; e-mail: christopher.lindberg{at}vgregion.se

The authors performed an open, randomized trial in patients with inclusion body myositis comparing 1) 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group) with 2) 12-month MTX treatment preceded by 7 days of IV anti–T-lymphocyte immunoglobulin treatment (ATG group). Eleven patients were randomized; 10 patients completed 12 months follow-up. Myometry showed that patients in the ATG group (n = 6) increased in mean muscle strength by 1.4% compared with the MTX group (n = 5), whose muscle strength decreased by 11.1% (p = 0.021).

This article has been cited by other articles:

				A A Amato and R J Barohn Inclusion body myositis: old and new concepts J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1186 - 1193. [Abstract] [Full Text] [PDF]

				M. C. Dalakas, G. Rakocevic, J. Schmidt, M. Salajegheh, B. McElroy, M. O. Harris-Love, J. A. Shrader, E. W. Levy, J. Dambrosia, R. L. Kampen, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis Brain, June 1, 2009; 132(6): 1536 - 1544. [Abstract] [Full Text] [PDF]

				J. C. Novak, A. E. Lovett-Racke, and M. K. Racke Monoclonal Antibody Therapies and Neurologic Disorders Arch Neurol, September 1, 2008; 65(9): 1162 - 1165. [Abstract] [Full Text] [PDF]

				S. A. Greenberg Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications Neurology, November 20, 2007; 69(21): 2008 - 2019. [Abstract] [Full Text] [PDF]

				A C Cordeiro and D A Isenberg Treatment of inflammatory myopathies. Postgrad. Med. J., July 1, 2006; 82(969): 417 - 424. [Abstract] [Full Text] [PDF]

				M. C. Dalakas Inflammatory, immune, and viral aspects of inclusion-body myositis Neurology, January 24, 2006; 66(1_suppl_1): S33 - S38. [Abstract] [Full Text] [PDF]

				R. C. Griggs The current status of treatment for inclusion-body myositis Neurology, January 24, 2006; 66(1_suppl_1): S30 - S32. [Abstract] [Full Text] [PDF]

				J. Schmidt, G. Rakocevic, R. Raju, and M. C. Dalakas Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity Brain, May 1, 2004; 127(5): 1182 - 1190. [Abstract] [Full Text] [PDF]